Inhibikase Therapeutics, Inc. filed a Form 8-K on August 26, 2026, disclosing that its Audit Committee dismissed CohnReznick LLP as the company's independent registered public accounting firm on August 21, 2026, and immediately appointed Deloitte & Touche LLP in its place.
Key Highlights
- Auditor dismissed: CohnReznick LLP was dismissed as Inhibikase Therapeutics' independent registered public accounting firm effective August 21, 2026.
- New auditor appointed: Deloitte & Touche LLP was appointed for the fiscal year ending December 31, 2026, effective immediately following the dismissal.
- Clean audit reports: CohnReznick's reports on the fiscal years ended December 31, 2025 and 2024 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified.
- No disagreements: The filing states there were no disagreements between the company and CohnReznick on accounting principles, financial statement disclosure, or auditing scope during the covered periods.
- Prior material weakness: During fiscal year 2024, CohnReznick advised the company that a material weakness existed in internal control over financial reporting; the filing states it was subsequently remediated by prior management.
- No prior Deloitte consultation: According to the filing, neither the company nor anyone acting on its behalf consulted with Deloitte on accounting or auditing matters during the fiscal years ended December 31, 2025 and 2024 or the subsequent interim period.
Inhibikase Therapeutics Audit Committee Action: CohnReznick Out, Deloitte In
According to the Form 8-K filed with the Securities and Exchange Commission, the Audit Committee of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) voted on August 21, 2026, to dismiss CohnReznick LLP and appoint Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. Both actions were described as effective immediately, with Deloitte's engagement beginning directly upon CohnReznick's dismissal.
The filing reports that CohnReznick's audit reports for the fiscal years ended December 31, 2025 and 2024 carried no adverse opinion, disclaimer of opinion, or qualification related to uncertainty, audit scope, or accounting principles. The company also disclosed that no disagreements arose between the company and CohnReznick on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure through the date of dismissal.
One reportable event was noted: during fiscal year 2024, CohnReznick advised the company of a material weakness in internal control over financial reporting. The filing states this weakness "was previously disclosed in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 and was subsequently remediated by prior management of the Company, as disclosed in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024." No other reportable events were identified for the covered periods. A letter from CohnReznick to the SEC, dated August 26, 2026, was filed as Exhibit 16.1. The report was signed by Mark Iwicki, Chief Executive Officer.
What Was Disclosed
Inhibikase Therapeutics disclosed the dismissal of CohnReznick LLP and appointment of Deloitte & Touche LLP as auditor, confirmed no disagreements with the outgoing firm, noted a previously remediated 2024 material weakness, and filed CohnReznick's confirmatory letter as Exhibit 16.1.





Please wait processing your request...